

Published Research -SQCCCRC

Genitourinary Cancers Program (2023)

1. Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin,MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Jones CU, Horwitz EM, et.al. [Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial](#).2023/5/12; Journal: European urology; <https://doi.org/10.1016/j.eururo.2023.04.024>

Research: This multi-institutional randomized RTOG study compared radiotherapy + Hormonal Therapy with or without chemotherapy in High-Risk Prostate Cancer.

Key benefit: This study rule out significant benefit of adjuvant chemotherapy.

2. Babu N, Al Amri I, Al Ghafri M, Gurmani MA, Al Fishawy M, Pervez N, AlMandhari Z. Low dose rate (LDR) -Prostate permanent implant – Role and importance of medical physicist. 2023 May.
Conference: MEFOMP 2023

